Key Points
- COO Julie Rubinstein sold 19,060 shares on April 24 at $14.02 for $267,221.20, leaving her with 382,132 shares (a 4.75% reduction); the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- The April 24 sale is part of a sustained selling program since March 23, with Rubinstein repeatedly selling ~19,060-share blocks and two 30,941-share blocks across multiple days.
- Adaptive Biotechnologies trades around $14 (market cap ~$2.18B), reported revenue up ~51% year-over-year and an EPS beat despite remaining unprofitable, and carries a MarketBeat consensus rating of "Moderate Buy" with a $18.25 target.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company's stock in a transaction on Friday, April 24th. The stock was sold at an average price of $14.02, for a total transaction of $267,221.20. Following the completion of the sale, the chief operating officer owned 382,132 shares of the company's stock, valued at approximately $5,357,490.64. The trade was a 4.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Wednesday, April 22nd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.13, for a total transaction of $269,317.80.
- On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.66, for a total transaction of $453,595.06.
- On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.55, for a total transaction of $277,323.00.
- On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.18, for a total transaction of $270,270.80.
- On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total transaction of $250,639.00.
- On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total transaction of $243,396.20.
- On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total value of $275,417.00.
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total value of $263,599.80.
Adaptive Biotechnologies Trading Up 2.3%
Shares of Adaptive Biotechnologies stock opened at $14.14 on Friday. The business's fifty day simple moving average is $14.50 and its 200 day simple moving average is $15.97. Adaptive Biotechnologies Corporation has a 12 month low of $7.16 and a 12 month high of $20.76. The firm has a market capitalization of $2.18 billion, a P/E ratio of -35.35 and a beta of 2.29.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the prior year, the company earned ($0.23) EPS. The business's revenue for the quarter was up 51.0% on a year-over-year basis. Analysts predict that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Brighton Jones LLC raised its stake in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock valued at $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC lifted its holdings in Adaptive Biotechnologies by 2.2% during the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock valued at $641,000 after purchasing an additional 904 shares during the last quarter. California State Teachers Retirement System boosted its position in Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock worth $1,145,000 after purchasing an additional 933 shares during the period. Captrust Financial Advisors boosted its position in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after purchasing an additional 1,119 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Adaptive Biotechnologies by 3.7% in the third quarter. Arizona State Retirement System now owns 31,443 shares of the company's stock worth $470,000 after purchasing an additional 1,120 shares in the last quarter. Institutional investors own 99.17% of the company's stock.
Wall Street Analysts Forecast Growth
ADPT has been the subject of several research reports. TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Monday. JPMorgan Chase & Co. boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.
Get Our Latest Stock Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
